KR20110036191A - Method for preparing active piperidine compound by optical separation - Google Patents
Method for preparing active piperidine compound by optical separation Download PDFInfo
- Publication number
- KR20110036191A KR20110036191A KR1020090093724A KR20090093724A KR20110036191A KR 20110036191 A KR20110036191 A KR 20110036191A KR 1020090093724 A KR1020090093724 A KR 1020090093724A KR 20090093724 A KR20090093724 A KR 20090093724A KR 20110036191 A KR20110036191 A KR 20110036191A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- added
- chlorophenyl
- vii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000003287 optical effect Effects 0.000 title claims abstract description 11
- 238000000926 separation method Methods 0.000 title claims abstract description 8
- -1 piperidine compound Chemical class 0.000 title description 13
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims abstract description 15
- 125000006239 protecting group Chemical group 0.000 claims abstract description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 2
- 239000000460 chlorine Chemical group 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 150000002366 halogen compounds Chemical class 0.000 claims 1
- OTZYADIPHOGUDN-KRWDZBQOSA-N 2-[(s)-(4-chlorophenyl)-piperidin-4-yloxymethyl]pyridine Chemical compound C1=CC(Cl)=CC=C1[C@@H](C=1N=CC=CC=1)OC1CCNCC1 OTZYADIPHOGUDN-KRWDZBQOSA-N 0.000 abstract description 5
- 238000007429 general method Methods 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 66
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 38
- 239000012044 organic layer Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000010410 layer Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 239000008213 purified water Substances 0.000 description 17
- 238000010992 reflux Methods 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 241001442129 Myosotis Species 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 10
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- KDISMIMTGUMORD-UHFFFAOYSA-N N-acetylpiperidine Natural products CC(=O)N1CCCCC1 KDISMIMTGUMORD-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- MIOPJNTWMNEORI-MHPPCMCBSA-N [(4r)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-MHPPCMCBSA-N 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- NZVZVGPYTICZBZ-UHFFFAOYSA-N 1-benzylpiperidine Chemical compound C=1C=CC=CC=1CN1CCCCC1 NZVZVGPYTICZBZ-UHFFFAOYSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- ZFUPOFQRQNJDNS-UHFFFAOYSA-N (4-chlorophenyl)-pyridin-2-ylmethanol Chemical compound C=1C=CC=NC=1C(O)C1=CC=C(Cl)C=C1 ZFUPOFQRQNJDNS-UHFFFAOYSA-N 0.000 description 3
- PHNPWISXEGFAHM-UHFFFAOYSA-N (4-hydroxypiperidin-1-yl)-phenylmethanone Chemical compound C1CC(O)CCN1C(=O)C1=CC=CC=C1 PHNPWISXEGFAHM-UHFFFAOYSA-N 0.000 description 3
- KZPIFQYDCVCSDS-UHFFFAOYSA-N 1-(4-hydroxypiperidin-1-yl)ethanone Chemical compound CC(=O)N1CCC(O)CC1 KZPIFQYDCVCSDS-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 3
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 3
- 229960002071 bepotastine Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- IBWOBPCKANNSAF-UHFFFAOYSA-N (4-bromopiperidin-1-yl)-phenylmethanone Chemical compound C1CC(Br)CCN1C(=O)C1=CC=CC=C1 IBWOBPCKANNSAF-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IJQWPBRRNBHHRW-UHFFFAOYSA-N 1-(4-bromopiperidin-1-yl)ethanone Chemical compound CC(=O)N1CCC(Br)CC1 IJQWPBRRNBHHRW-UHFFFAOYSA-N 0.000 description 2
- PKUIJUARWDHLHB-UHFFFAOYSA-N 1-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1OC(C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 PKUIJUARWDHLHB-UHFFFAOYSA-N 0.000 description 2
- BIVWVMVLXIUILP-UHFFFAOYSA-N 1-benzyl-4-bromopiperidine Chemical compound C1CC(Br)CCN1CC1=CC=CC=C1 BIVWVMVLXIUILP-UHFFFAOYSA-N 0.000 description 2
- BPPZXJZYCOETDA-UHFFFAOYSA-N 1-benzylpiperidin-4-ol Chemical compound C1CC(O)CCN1CC1=CC=CC=C1 BPPZXJZYCOETDA-UHFFFAOYSA-N 0.000 description 2
- DJEPVOXJGPSEMV-UHFFFAOYSA-N 2-[(1-benzylpiperidin-4-yl)oxy-(4-chlorophenyl)methyl]pyridine Chemical compound C1=CC(Cl)=CC=C1C(C=1N=CC=CC=1)OC1CCN(CC=2C=CC=CC=2)CC1 DJEPVOXJGPSEMV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- VAZYQWDCKIMRJI-FYZYNONXSA-N C12(C(=O)CC(CC1)C2(C)C)CS(=O)(=O)O.ClC2=CC=C(C=C2)[C@H](OC2CCN(CC2)C(C)=O)C2=NC=CC=C2 Chemical compound C12(C(=O)CC(CC1)C2(C)C)CS(=O)(=O)O.ClC2=CC=C(C=C2)[C@H](OC2CCN(CC2)C(C)=O)C2=NC=CC=C2 VAZYQWDCKIMRJI-FYZYNONXSA-N 0.000 description 2
- RMIFSCXWPYWITK-BQAIUKQQSA-N C12(C(=O)CC(CC1)C2(C)C)CS(=O)(=O)O.ClC2=CC=C(C=C2)[C@H](OC2CCN(CC2)C(C2=CC=CC=C2)=O)C2=NC=CC=C2 Chemical compound C12(C(=O)CC(CC1)C2(C)C)CS(=O)(=O)O.ClC2=CC=C(C=C2)[C@H](OC2CCN(CC2)C(C2=CC=CC=C2)=O)C2=NC=CC=C2 RMIFSCXWPYWITK-BQAIUKQQSA-N 0.000 description 2
- NKWDHTOIZDLUFK-JIDHJSLPSA-N C12(C(=O)CC(CC1)C2(C)C)CS(=O)(=O)O.ClC2=CC=C(C=C2)[C@H](OC2CCN(CC2)CC2=CC=CC=C2)C2=NC=CC=C2 Chemical compound C12(C(=O)CC(CC1)C2(C)C)CS(=O)(=O)O.ClC2=CC=C(C=C2)[C@H](OC2CCN(CC2)CC2=CC=CC=C2)C2=NC=CC=C2 NKWDHTOIZDLUFK-JIDHJSLPSA-N 0.000 description 2
- BWWVQGJNSSSGFZ-UHFFFAOYSA-N ClC1=CC=C(C=C1)C(OC1CCN(CC1)C(C1=CC=CC=C1)=O)C1=NC=CC=C1 Chemical compound ClC1=CC=C(C=C1)C(OC1CCN(CC1)C(C1=CC=CC=C1)=O)C1=NC=CC=C1 BWWVQGJNSSSGFZ-UHFFFAOYSA-N 0.000 description 2
- HGUQRHAFHQJTGR-XJDOXCRVSA-N ClC1=CC=C(C=C1)C(OC1CCN(CC1)[C@H](C(=O)O)CC)C1=NC=CC=C1 Chemical compound ClC1=CC=C(C=C1)C(OC1CCN(CC1)[C@H](C(=O)O)CC)C1=NC=CC=C1 HGUQRHAFHQJTGR-XJDOXCRVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- BWWVQGJNSSSGFZ-QHCPKHFHSA-N [4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]-phenylmethanone Chemical compound Clc1ccc(cc1)[C@H](OC1CCN(CC1)C(=O)c1ccccc1)c1ccccn1 BWWVQGJNSSSGFZ-QHCPKHFHSA-N 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OCQAXYHNMWVLRH-QZTJIDSGSA-N (2r,3r)-2,3-dibenzoyl-2,3-dihydroxybutanedioic acid Chemical compound O=C([C@@](O)(C(=O)O)[C@](O)(C(O)=O)C(=O)C=1C=CC=CC=1)C1=CC=CC=C1 OCQAXYHNMWVLRH-QZTJIDSGSA-N 0.000 description 1
- PKUIJUARWDHLHB-IBGZPJMESA-N 1-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]ethanone Chemical compound CC(=O)N1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1 PKUIJUARWDHLHB-IBGZPJMESA-N 0.000 description 1
- MDJUTZFVMBSYLR-UHFFFAOYSA-N 1-acetylpyridin-4-one Chemical compound CC(=O)N1C=CC(=O)C=C1 MDJUTZFVMBSYLR-UHFFFAOYSA-N 0.000 description 1
- DJEPVOXJGPSEMV-DEOSSOPVSA-N C1=CC(Cl)=CC=C1[C@@H](C=1N=CC=CC=1)OC1CCN(CC=2C=CC=CC=2)CC1 Chemical compound C1=CC(Cl)=CC=C1[C@@H](C=1N=CC=CC=1)OC1CCN(CC=2C=CC=CC=2)CC1 DJEPVOXJGPSEMV-DEOSSOPVSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- HYBKJNBSKZCUPH-LMOVPXPDSA-N ClC1=CC=C(C=C1)[C@H](OC1CCNCC1)C1=NC=CC=C1.[P] Chemical compound ClC1=CC=C(C=C1)[C@H](OC1CCNCC1)C1=NC=CC=C1.[P] HYBKJNBSKZCUPH-LMOVPXPDSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Abstract
본 발명은 하기화학식 (Ⅱ)의 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘의 제조 방법에 관한 것으로서, 더욱 상세하게는 (±)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘-1-일-R(Ⅲ)화합물을 종전의 공지 방법과는 다른 방법으로 제조하여 이를 광학 활성 분리제를 이용 고순도, 고수율로 광학 분리를 한 후, 일반적인 방법으로 보호기 (R)을 제거하여 고 광학 순도의 목적화합물 (Ⅱ)을 얻는 제조방법에 관한 것이다.The present invention relates to a method for preparing (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidine of the following general formula (II), more specifically (±) -4- [(4-Chlorophenyl) -2-pyridylmethoxy] piperidin-1-yl-R (III) compound was prepared by a method different from the conventionally known methods, and was prepared using an optically active separating agent. After the optical separation in the yield, the protective group (R) is removed by a general method to obtain a target compound (II) of high optical purity.
상기 식에서, Where
R은 아세틸기, 벤조일기, 벤질기 등의 아미노 보호기이다.R is amino protecting groups, such as an acetyl group, a benzoyl group, and a benzyl group.
Description
본 발명은 항히스타민 활성 및 항알레르기 활성이 우수한 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리디노 부탄산 (Ⅰ)의 벤젠 설폰산 염 또는 벤조산 염의 핵심 중간체인 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘(Ⅱ)의 새로운 제조방법에 관한 것이다.The present invention provides a key intermediate of the benzene sulfonic acid salt or benzoic acid salt of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidino butanoic acid (I), which has excellent antihistamine activity and antiallergic activity. A novel process for the preparation of phosphorus (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidine (II).
본 발명은 공지된 제조방법보다 화학식 (Ⅱ) 화합물을 고순도로 보다 용이하게 제조할 수 있음을 특징으로 한다.The present invention is characterized in that the compound of formula (II) can be produced more easily and with higher purity than a known production method.
상기화학식 (Ⅰ)로 표시되는 베포타스틴(bepotastine)은 화학명이 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리디노 부탄산의 벤젠 설폰산 염 또는 벤조산 염이며, 강력한 항히스타민 활성 및 항알레르기 활성을 나타낸다. Bepotastine represented by the formula (I) is a benzene sulfonic acid salt or benzoic acid having a chemical name of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidino butanoic acid. Salt, and exhibits strong antihistamine activity and antiallergic activity.
종전의 제조방법으로는 미국특허 제4929638호, 유럽특허 제335586, 949260호 등이 있으며, 특히, 일본 공개특허 평 2-25465호는 베포타스틴을 라세믹체 화합물로서 최초로 개시하였으며 일본 특허 공개 제2000-198784호에는 라세믹체 화합물 (Ⅱ)를 광학활성 프로피온산 화합물 (Ⅳ) 또는 광학활성 N-아실-아미노산을 작용시키고 생성된 2 종의 부분입체 이성질체 염을 용해도 차이를 이용하여 난용성의 부분입체 이성질체 염을 분리 채취하고, 이어서 이 염을 분해하여 얻어진 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘에 화학식 (Ⅴ)로 표시되는 할로겐산 에스터를 작용시켜 유리 베포타스틴 (Ⅵ)을 얻고, 이를 가수분해하여 (Ⅰ) 화합물을 얻은 후, 다시 벤젠설폰산 또는 벤조산과 염 형성 반응을 시켜 상기화학식 (Ⅰ)로 표시되는 광학활성 피페리딘 화합물 (Ⅰ)의 벤젠설폰산 염 또는 벤조산 염의 제조방법 에 관한 것이다.Conventional manufacturing methods include US Pat. No. 4,953,638, European Patent No. 335586, 949260, and the like. In particular, Japanese Patent Application Laid-Open No. 2-25465 discloses bepotastine as a racemic compound for the first time. -198784 discloses a racemic compound (II) which reacts with an optically active propionic acid compound (IV) or an optically active N-acyl-amino acid and generates two types of diastereomeric salts using different solubility solubility diastereomers. The salt is separated and the halogen acid ester represented by the formula (V) is applied to (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidine obtained by decomposing the salt. To obtain free bepotastine (VI), and hydrolyze it to obtain compound (I), followed by further salt formation reaction with benzenesulfonic acid or benzoic acid to give an optically active piperidine compound represented by the above formula (I) Ⅰ) It relates to a process for preparing benzenesulfonic acid salts or benzoic acid salts.
상기 식중 R은 메틸기, 에틸기 등의 저급 알킬기를 나타내고, W는 할로겐 원 자 등의 이탈기 또는 메탄술포닐 옥시기, p-톨루엔 술포닐옥시기 등의 반응성 에스터기를 나타내며, Y는 수소원자 또는 할로겐 원자이고, Z는 저급알콕시기를 나타낸다.In the above formula, R represents a lower alkyl group such as methyl group or ethyl group, W represents leaving group such as halogen atom or reactive ester group such as methanesulfonyl oxy group, p-toluene sulfonyloxy group, and Y represents hydrogen atom or halogen atom And Z represents a lower alkoxy group.
그러나 상기와 같은 종래방법은 반응공정이 까다롭고, 복잡하며 순도 또한 바람직하지 못하였다.However, the conventional method as described above is difficult to react, complicated and purity is also undesirable.
본 발명은 반응공정을 더욱 간소화하고 고순도의 목적물 (Ⅱ) 화합물을 얻기 위함이다.The present invention is to further simplify the reaction process and to obtain a high purity target compound (II).
본 발명자들은 공지된 방법에 의해 광학적으로 분할된 화학식 (Ⅶ) 화합물을 화학식 (Ⅷ) 화합물과 축합시켜 광학활성체인 화학식 (Ⅲ) 화합물을 얻거나 화학식 (Ⅶ)의 라세믹 중간체를 화학식 (Ⅷ) 화합물과 축합시켜 화학식 (Ⅲ) 라세믹 화합물을 얻은 후, 이 화합물을 광학활성 분리제인 R-(-)-10-캄포설폰산 또는 (-)-디벤조일-D-타르타릭산을 이용하여 디아스테레오머성 염을 형성한 후, 적절한 용매를 이용하여 광학 분리하는 방법에 의해 광학 순도 및 화학적 순도가 높은 화학식 (Ⅱ)의 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘을 간편하게 제조하는 방법을 제공하는데 그 목적이 있다.The present inventors condensed the compound of formula (VII) optically divided by a known method with a compound of formula (VII) to obtain a compound of formula (III) which is an optically active compound or a racemic intermediate of formula (VII). After condensation with a compound to obtain a racemic compound of formula (III), the compound was subjected to dia using R-(-)-10-camphorsulfonic acid or (-)-dibenzoyl-D-tartaric acid as an optically active separating agent. (S) -4-[(4-chlorophenyl) -2-pyridylmethene of formula (II) having high optical purity and chemical purity by the method of optical separation using a suitable solvent after forming a stereomeric salt. It is an object of the present invention to provide a method for easily preparing oxy] piperidine.
상기의 본 발명은 반응공정이 매우 간편하고, 고순도로 목적물을 얻을 수 있다는 장점이 있다.The present invention described above has the advantage that the reaction process is very simple, and the target product can be obtained with high purity.
본 발명은 하기 반응공정 1에 나타낸 바와 같이, 공지의 방법, Tetrahedron Letters vol 37, No 32, pp 5675-5678 (1996): (S)-"Carbinoxamine의 부제합성"과 Bull.Chem.Soc.Jpn,. Vol 60, pp 2651-2655 (1987) "알파-아릴-2-피리딜메탄올의 제조"에서 제시한 바와 같이 화학식 (Ⅶ) 화합물을 제조한 후, (Ⅶ) 화합물을 화학식 (Ⅷ) 화합물과 축합시켜 화학식 (Ⅲ) 화합물을 제조하고 일반적인 방법에 의해 보호기를 제거하여 목적하는 중간체 (Ⅱ) 화합물을 제조한다. The present invention provides a well-known method, Tetrahedron Letters vol 37, No 32, pp 5675-5678 (1996): (S)-"Subsynthesis of Carbinoxamine" and Bull. Chem. Soc. Jpn ,. Vol 60, pp 2651-2655 (1987) After the preparation of the compound of formula (VIII) as shown in "Preparation of alpha-aryl-2-pyridylmethanol", the compound (v) is condensed with the compound of formula (VIII) To prepare the compound of formula (III) and to remove the protecting group by the general method to produce the desired intermediate (II) compound.
[반응공정 1] [Reaction Process 1]
상기 식에서, R은 아세틸, 벤조일, 벤질기이며,Wherein R is an acetyl, benzoyl, benzyl group,
X는 할로겐 즉 불소, 염소, 취소, 요오드이거나 알킬 혹은 아릴설포닐옥시기이다.X is halogen, fluorine, chlorine, cancelled, iodine or an alkyl or arylsulfonyloxy group.
좀더 상세하게 설명을 하면 화학식 (Ⅶ) 화합물을 화학식 (Ⅷ) 화합물과 반응시 톨루엔, 디옥산, 크실렌, 메틸이소부틸케톤 혹은 디메틸포름아미드 등과 같은 유기용매를 사용하여 80-140 ℃ 온도, 바람직하게는 100-140 ℃, 더욱 바람직 하기로는 120-140 ℃에서, 예를 들면 소디움카보네이트, 포타시움카보네이트, 중조, 소디움바이카보네이트 등과 같은 알카리금속카보네이트나 바이카보네이트의 산수용체 존재하 축합 반응을 진행시켜 화합물 (Ⅲ)을 얻고, 하기와 같은 일반적인 방법으로 보호기 (R)을 제거하여 화합물 (Ⅱ)를 얻는다.In more detail, when the compound of formula (V) is reacted with the compound of formula (V), an organic solvent such as toluene, dioxane, xylene, methyl isobutyl ketone or dimethylformamide may be used at a temperature of 80-140 ° C., preferably Is condensed at 100-140 ° C., more preferably 120-140 ° C., in the presence of an acid acceptor of an alkali metal carbonate or bicarbonate such as, for example, sodium carbonate, potassium carbonate, sodium bicarbonate, sodium bicarbonate, etc. (III) is obtained and the protecting group (R) is removed by the following general method to obtain compound (II).
즉, 이렇게 얻은 (Ⅲ) 화합물의 R이 벤질일 경우, 접촉환원법에 의해 벤질기를 절단한다.That is, when R of the compound (III) thus obtained is benzyl, the benzyl group is cleaved by the catalytic reduction method.
이때 사용하는 촉매는 팔라디움, 풀라티늄 등의 금속 촉매를 사용하거나 일반적인 벤질기 제거방법을 사용하여 보호기를 제거한다.At this time, the catalyst used may be removed by using a metal catalyst such as palladium, palladium, or a common benzyl group removal method.
R이 아세틸 혹은 벤조일일 경우, 염산 혹은 황산과 같은 무기산 수용액 6-10 N농도를 이용하여 환류하에 2-20 시간 동안, 바람직하기로는 6-14 시간 동안 환류하여 보호기를 제거한다.When R is acetyl or benzoyl, the protecting group is removed by refluxing for 2-20 hours, preferably 6-14 hours, under reflux using an aqueous 6-10 N concentration of an inorganic acid solution such as hydrochloric acid or sulfuric acid.
반응액을 유기용매 즉 에테르, 에틸아세테이트, 벤젠, 톨루엔, 크실렌 등과 같은 유기용매로 세척해준 후 진한 암모니아수, 소디움 혹은 포타시움 하이드록사이드 같은 강알카리 용액으로 알카리화 한 후 유기 용매로 추출해준다.The reaction solution is washed with an organic solvent such as ether, ethyl acetate, benzene, toluene, xylene, and the like, and then alkalinized with a strong alkali solution such as concentrated ammonia water, sodium or potassium hydroxide and extracted with an organic solvent.
이때 유기용매는 클로로포름, 메틸렌클로라이드, 벤젠, 크실렌, 톨루엔, 에틸아세테이트 등의 용매로 추출하여 화합물 (Ⅱ)를 얻는다.At this time, the organic solvent is extracted with a solvent such as chloroform, methylene chloride, benzene, xylene, toluene, ethyl acetate and the like to obtain compound (II).
또 다른 공정으로, 하기 반응공정 2에 나타낸 바와 같이, 상기 화학식 1 화합물의 공지 출발물질 제조방법의 참고문헌에서 제조방법을 제시한 하기 화학식 (Ⅶ) 화합물의 라세믹체 (Ⅶ') 화합물을 염화티오닐 클로라이드로 염소화시킨 후, 얻어진 화학식 (Ⅸ) 화합물에 화학식 (Ⅷ) 화합물을 축합시킨 다음, 얻어진 (±)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘-1-일-R(Ⅲ) 라세믹 혼합물을 광학 활성 분리제인 R-(-)-10-캄포설폰산 또는 (-)-디벤조일 타르타릭산을 반응시켜 고수율, 고순도로 라세믹체 혼합물 중에서 (S)체만을 광학 분리한 후, 일반적인 방법으로 보호기 (R)을 제거하여 구조식 (Ⅱ) 화합물을 제조한다.In another process, as shown in Reaction Step 2, a racemic compound (VII ') of the compound of formula (VII) After chlorination with onyl chloride, the compound of formula (V) is condensed to the obtained compound of formula (VII), and then (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidine- is obtained. The 1-yl-R (III) racemic mixture was reacted with R-(-)-10-camphorsulfonic acid or (-)-dibenzoyl tartaric acid as an optically active separating agent in a racemic mixture in high yield, high purity ( After optical separation of only the S) body, the protecting group (R) is removed in a general manner to prepare the compound of formula (II).
[반응공정 2][Reaction Process 2]
상기 식에서, R은 위에서 정의한 바와 같으며, X는 하이드록실기이다.Wherein R is as defined above and X is a hydroxyl group.
상기 반응공정 2를 좀더 상세히 설명하면, 화학식 (Ⅶ)의 라세믹 화합물(Ⅶ')을 티오닐클로라이드, 삼브롬화인, 오브롬화인, 포스포러스옥시클로라이드 등의 할로겐화제로 할로겐화한 후, 얻어진 (Ⅶ) 화합물을 (Ⅷ) 화합물과 축합 시킨다.In more detail, the reaction step 2 is obtained by halogenating a racemic compound of formula (VII) with a halogenating agent such as thionyl chloride, phosphorus tribromide, phosphorus obromide, phosphorus oxychloride, ) Is condensed with the compound (iii).
본 반응시 톨루엔, 디옥산, 크실렌, 메틸이소부틸케톤 혹은 디메틸포름아미드 등과 같은 유기용매를 사용하거나 용매 없이 80-140 ℃, 바람직하기로는 100-140 ℃, 더욱 바람직하기로는 120-140 ℃에서, 예를 들면 소디움카보네이트, 포타시움카보네이트, 중조, 소디움바이카보네이트 등과 같은 알카리금속카보네이트나 바이카보네이트의 산수용체 존재하 축합 반응을 진행시켜 화합물 (Ⅱ)를 얻는다.In the reaction, using an organic solvent such as toluene, dioxane, xylene, methyl isobutyl ketone or dimethylformamide, or without solvent, at 80-140 ℃, preferably 100-140 ℃, more preferably 120-140 ℃, For example, compound (II) is obtained by conducting a condensation reaction in the presence of an acid acceptor of an alkali metal carbonate or bicarbonate such as sodium carbonate, potassium carbonate, sodium bicarbonate and sodium bicarbonate.
이렇게 얻은 화합물 (Ⅱ)를 아세톤 용매하에서 R-(-)-10-캄포설폰산 또는 (-)-디벤조일 타르타릭산과 같은 광학적 활성을 갖는 산으로 라세믹 화합물을 염화 시킨 후, 일정한 광학적 회전을 나타내는 생성물이 얻어질 때까지 상기 염을 연속적으로 재결정화 하고 염기에 의해 그 염으로부터 좌회전성 이성질체를 방출시킴으로써, 목적화합물로 우수한 순도를 갖는 화학식 (Ⅱ) 화합물을 얻는다.Compound (II) thus obtained is chlorinated with a racemic compound with an acid having optical activity such as R-(-)-10-camphorsulfonic acid or (-)-dibenzoyl tartaric acid in acetone solvent, followed by constant optical rotation. By continuously recrystallizing the salts until the product indicated is obtained and releasing left-rotating isomers from the salts with a base, the compound of formula (II) having excellent purity as the target compound is obtained.
이렇게 얻어진 화학식 (Ⅱ) 염 화합물을 적절한 유기용매 중에서 추가로 재결정화시켜 바람직하게는 수율이 60-80 %이고, 광학 순도가 높은 화합물 (Ⅱ)의 R-(-)-10-캄포설폰산 염 또는 (-)-디벤조일 타르타릭산 염을 제조한다.The thus obtained formula (II) salt compound is further recrystallized in a suitable organic solvent, preferably R-(-)-10-camphorsulfonic acid salt of compound (II) having a yield of 60-80% and high optical purity. Or (-)-dibenzoyl tartaric acid salt.
광학적 순도는 적어도 약 95-99.9 %, 바람직하게는 약 98-99.9 %이다.Optical purity is at least about 95-99.9%, preferably about 98-99.9%.
바람직한 공용매는 디메틸 포름 아미드, 디메틸설폭시드, 톨루엔, 헵탄, 디메틸아세트아미드로 구성된 군에서 선택된다.Preferred cosolvents are selected from the group consisting of dimethyl formamide, dimethyl sulfoxide, toluene, heptane, dimethylacetamide.
바람직한 산수용체는 염기이다.Preferred acid acceptors are bases.
그 정의는 상기에서 제시한 바와 같으며 사용몰수는 1-4 배몰수이다.The definition is as set forth above and the number of moles used is 1-4 times the number of moles.
이상에서 설명한 바를, 다음의 실시예에 의거하여 더욱 상세히 설명하겠는바, 본 발명이 이에 한정되는 것은 아니다.The bar described above will be described in more detail based on the following examples, but the present invention is not limited thereto.
[[ 실시예Example ]]
( 실시예 1) 4-하이드록시-1-벤조일 피페리딘의 제조 (Example 1) Preparation of 4-hydroxy-1-benzoyl-piperidine
디클로로메탄 1,200 ml에 소디움보로하이드라이드 5.5 g을 가하고 실온에서 교반하면서 1-벤조일-4-피페리딘 24 g을 디클로로메탄 80 ml에 가해 용해한 후, 상기온도를 유지하면서 서서히 적가한다.5.5 g of sodium borohydride is added to 1,200 ml of dichloromethane, and 24 g of 1-benzoyl-4-piperidine is added to 80 ml of dichloromethane while stirring at room temperature, followed by dropwise addition while maintaining the above temperature.
완전히 가하고 나서 실온으로 온도를 상승시킨 후, 동일 온도에서 6 시간 동안 교반한다.After complete addition, the temperature is raised to room temperature and then stirred at the same temperature for 6 hours.
반응이 완료된 것을 확인한 후 포화 중조수용액 1,200 ml에 서서히 가해주고나서 동일 온도에서 10 분간 교반한다.After confirming that the reaction was completed, slowly added to 1,200 ml of saturated aqueous sodium bicarbonate solution and stirred for 10 minutes at the same temperature.
층분리를 하여 유기층을 증류수 500 ml로 세척하고 무수 황산 마그네슘 5 g으로 건조한 후 여과한다.The layers were separated and the organic layer was washed with 500 ml of distilled water, dried over 5 g of anhydrous magnesium sulfate, and filtered.
여액을 감압에 이해 제거하면 오일상의 표제 목적화합물 20 g (수율 82 %)을 얻는다.The filtrate was removed under reduced pressure to give 20 g (yield 82%) of the title compound as an oil.
1H NMR (CDCl3) : δ 1.96(4H, -CH2-), 2.24(4H, -CH2-), 3.44(1H), 7.44(2H, 방향핵), 7.51(1H, 방향핵), 7.95(2H, 방향핵)1 H NMR (CDCl 3): δ 1.96 (4H, -CH 2-), 2.24 (4H, -CH 2-), 3.44 (1H), 7.44 (2H, aromatic core), 7.51 (1H, aromatic core), 7.95 (2H, Direction nucleus)
( 실시예 2) 4-하이드록시-1-아세틸 피페리딘의 제조 ( Example 2) Preparation of 4-hydroxy-1-acetyl piperidine
디클로로메탄 50 ml에 소디움보로하이드라이드 0.69 g을 가하고 실온에서 1-아세틸-4-피리돈 0.9 ml을 가하고 약 10 시간 동안 교반한다.Add 0.69 g of sodium borohydride to 50 ml of dichloromethane, add 0.9 ml of 1-acetyl-4-pyridone at room temperature and stir for about 10 hours.
반응이 완료된 후 반응액을 포화 중조수용액 50 ml에 가하고 10 분간 교반한다.After the reaction was completed, the reaction solution was added to 50 ml of saturated aqueous sodium bicarbonate solution and stirred for 10 minutes.
디클로로메탄 100 ml로 2 회 추출한다.Extract twice with 100 ml of dichloromethane.
유기층을 정제수 50 ml로 2 회 세척한 후 무수 망초 5 g으로 건조한다.The organic layer was washed twice with 50 ml of purified water and dried over 5 g of dry forget-me-not.
여과를 하고 여액을 감압에 의해 제거하여 상기 표제 목적화합물 0.8 g (수율 86.8 %)를 얻는다.Filtration and removal of the filtrate by reduced pressure yielded 0.8 g (86.8%) of the title compound.
1H NMR (CDCl3) : δ 1.65(4H, -CH2-), 2.0(1H, -OH), 2.02(3H, -CH3), 3.34(4H, -CH2-)1 H NMR (CDCl 3): δ 1.65 (4H, -CH 2-), 2.0 (1H, -OH), 2.02 (3H, -CH 3), 3.34 (4H, -CH 2-)
( 실시예 3) 4-브로모-1-벤조일 피페리딘의 제조 (Example 3) Preparation of 4-bromo-1-benzoyl-piperidine
4-하이드록시-1-벤조일 피페리딘 20 g을 벤젠 80 ml에 가해 용해한다.20 g of 4-hydroxy-1-benzoyl piperidine are added to 80 ml of benzene and dissolved.
삼브롬화 인 11 ml을 서서히 가하고 가열하여 3 시간 동안 환류한다.11 ml of phosphorus tribromide are slowly added and heated to reflux for 3 hours.
반응이 완료된 것을 확인하고 실온으로 냉각한다.Confirm that the reaction is complete and cool to room temperature.
반응액에 정제수 200 ml을 가하고 실온에서 10 분간 교반한 후 층분리를 한 다음, 유기층을 취하여 정제수 50 ml로 2 회 세척한다.200 ml of purified water was added to the reaction solution, the mixture was stirred at room temperature for 10 minutes, followed by layer separation. The organic layer was taken out and washed twice with 50 ml of purified water.
유기층을 무수 망초로 건조한 후 여과한다.The organic layer is dried over anhydrous forget-me-not and filtered.
여액을 진공으로 제거하여 오일상의 상기 표제 목적화합물 11.6 g(수율 45 %)을 얻는다.The filtrate is removed in vacuo to give 11.6 g (45% yield) of the title compound as an oil.
1H NMR (CDCl3) : δ 1.96(4H, -CH2-), 3.34(4H, -CH2-), 3.44(1H), 7.44(2H, 방향핵), 7.51(1H), 7.95(2H)1 H NMR (CDCl 3): δ 1.96 (4H, -CH 2-), 3.34 (4H, -CH 2-), 3.44 (1H), 7.44 (2H, aromatic nucleus), 7.51 (1H), 7.95 (2H)
( 실시예 4) 4-브로모-1-벤질피페리딘의 제조 (Example 4) Preparation of 4-bromo-1-benzyl piperidine
4-하이드록시-1-벤질피페리딘 0.83 g을 벤젠 4 ml에 가해 용해한 후 삼브로모인 1.43 g을 가한다.0.83 g of 4-hydroxy-1-benzylpiperidine is added to 4 ml of benzene and dissolved, followed by 1.43 g of tribromoin.
가온하여 5 시간 동안 환류한 다음 실온으로 냉각한다.Warm to reflux for 5 hours and then cool to room temperature.
반응액에 냉수 5 ml을 가하고 5 분간 교반한 다음 진한 암모니아수로 강하게 알카리화한다. 5 ml of cold water is added to the reaction mixture, which is stirred for 5 minutes, followed by strong alkaline with concentrated ammonia water.
층분리를 하여 유기층을 취하고 정제수 2 ml로 2 회 세척한다.The layers are separated and the organic layer is taken and washed twice with 2 ml of purified water.
유기층을 무수 망초로 건조하고 여과 후 여액을 감압에 의해 제거하여 상기 표제 목적화합물 0.35 g (수율 32 %)을 얻는다.The organic layer is dried over anhydrous forget-me-not, filtered and the filtrate is removed by reduced pressure to give 0.35 g (yield 32%) of the title compound.
1H NMR (CDCl3) : δ 1.96(4H, -CH2-), 3.24(4H, -CH2-), 3.44(1H), 3.62(2H, -CH2-), 7.06(2H, 방향핵), 7.07(1H, 방향핵), 7.14(2H, 방향핵)1 H NMR (CDCl3): δ 1.96 (4H, -CH2-), 3.24 (4H, -CH2-), 3.44 (1H), 3.62 (2H, -CH2-), 7.06 (2H, aromatic nucleus), 7.07 (1H) , Direction nucleus), 7.14 (2H, direction nucleus)
( 실시예 5) 4-브로모-1-아세틸피페리딘의 제조 (Example 5) Preparation of 4-Bromo-1-Acetyl-piperidine
4-하이드록시-1-아세틸피페리딘 0.83 g을 벤젠 4 ml에 가해 용해한 후 삼브로모인 1.43 g을 가한다.0.83 g of 4-hydroxy-1-acetylpiperidine is added to 4 ml of benzene to dissolve, followed by 1.43 g of tribromoin.
가온하여 5 시간 동안 환류한 다음 실온으로 냉각한다.Warm to reflux for 5 hours and then cool to room temperature.
반응액에 냉수 5 ml을 가하고 5 분간 교반한 다음 진한 암모니아수로 강하게 알카리화한다. 5 ml of cold water is added to the reaction mixture, which is stirred for 5 minutes, followed by strong alkaline with concentrated ammonia water.
층분리를 하여 유기층을 취하고 정제수 2 ml로 2 회 세척한다.The layers are separated and the organic layer is taken and washed twice with 2 ml of purified water.
유기층을 무수 망초로 건조하고 여과 후 여액을 감압에 의해 제거하여 상기 표제 목적화합물 0.42 g (수율 35 %)을 얻는다.The organic layer was dried over anhydrous forget-me-not, filtered and the filtrate was removed by reduced pressure to give 0.42 g (yield 35%) of the title compound.
1H NMR (CDCl3) : δ 1.96(4H, -CH2-), 2.03(3H), 3.24(4H, -CH2-), 3.44(1H)1 H NMR (CDCl 3): δ 1.96 (4H, -CH 2-), 2.03 (3H), 3.24 (4H, -CH 2-), 3.44 (1H)
( 실시예 6) 알파-p-클로로페닐-2-피리딘 클로로 메탄의 제조 ( Example 6) Preparation of alpha-p-chlorophenyl-2-pyridine chloromethane
알파-p-클로로페닐-2-피리딘 메탄올 8 g을 벤젠 54 ml에 가하고 용해한 다음 냉각한다.8 g of alpha-p-chlorophenyl-2-pyridine methanol are added to 54 ml of benzene, dissolved and cooled.
이용액에 티오닐클로라이드 6 ml을 가하고 상온에서 하룻밤 교반한다.6 ml of thionyl chloride is added to the solution, and the mixture is stirred overnight at room temperature.
반응이 완료된 후 10 % 암모니아수 50 ml을 가해 알카리화 한 다음 층분리를 한다.After the reaction was completed, 50 ml of 10% aqueous ammonia was added to the mixture, followed by layer separation.
유기층을 무수 망초로 건조하고 여과하여 여액을 감압에 의해 제거한다.The organic layer is dried over anhydrous forget-me-not and filtered to remove the filtrate by reduced pressure.
상기 표제 목적화합물 6 g (수율 70 %)를 얻는다.6 g (yield 70%) of the title compound are obtained.
1H NMR (CDCl3) : δ 6.04(1H), 7.18(1H), 7.20(2H), 7.27(2H), 7.50(1H), 7.67(1H), 8.61(1H)1 H NMR (CDCl 3): δ 6.04 (1H), 7.18 (1H), 7.20 (2H), 7.27 (2H), 7.50 (1H), 7.67 (1H), 8.61 (1H)
( 실시예 7) 알파-[(p-클로로페닐-2-피리딘)메톡시]-1-벤조일-4-피페리딘의 제조 Example 7 alpha - [(p- chlorophenyl-2-pyridinyl) methoxy] Preparation of 1-benzoyl-4-piperidine
4-하이드록시-1-벤조일 피페리딘 0.55 g을 톨루엔 3 ml에 가하고 금속 소디움 62 mg을 실온에서 조심스럽게 가한다.0.55 g of 4-hydroxy-1-benzoyl piperidine is added to 3 ml of toluene and 62 mg of metal sodium are carefully added at room temperature.
완전히 가하고 나서 금속소디움이 모두 용해될 때까지 가열 교반한다.After complete addition, the mixture is heated and stirred until all of the metal sodium is dissolved.
그리고나서 알파-p-클로로페닐-2-피리딘 클로로 메탄 0.74 g을 톨루엔 3 ml에 용해하여 60 분간에 걸쳐 조심스럽게 서서히 가해준다.Then 0.74 g of alpha-p-chlorophenyl-2-pyridine chloromethane is dissolved in 3 ml of toluene and carefully added slowly over 60 minutes.
모두 가하고 나서 36 시간 동안 환류 교반한 다음 실온으로 냉각한다.After the addition, the mixture was stirred under reflux for 36 hours and then cooled to room temperature.
정제수 5 ml을 가하고 희염산 3 ml를 가해 세척해 준다.5 ml of purified water is added and 3 ml of dilute hydrochloric acid is added for washing.
층분리를 하여 유기층을 취하고, 무수 망초 0.1 g으로 건조하고 여과하여 유기용매를 감압에 의해 제거한다.The organic layer was separated by layer separation, dried over 0.1 g of anhydrous manganese, filtered and the organic solvent was removed by reduced pressure.
상기 표제 목적화합물 0.9 g (수율 82.6 %)를 얻는다.0.9 g (yield 82.6%) of the title compound is obtained.
1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 3.34(4H, -CH2-), 5.41(1H), 7.13(2H, 방향핵), 7.18(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1H NMR (CDCl3): δ 1.63 (4H, -CH2-), 2.85 (1H), 3.34 (4H, -CH2-), 5.41 (1H), 7.13 (2H, direction nucleus), 7.18 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)
( 실시예 8) (±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘의 제조 (Example 8) (±) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of benzyl piperidin-
4-하이드록시-1-벤질피페리딘 2.4 g, 소디움 카보네이트 2.7 g, 메틸이소부틸케톤 32 ml을 가하고 1 시간 동안 환류한다.2.4 g of 4-hydroxy-1-benzylpiperidine, 2.7 g of sodium carbonate and 32 ml of methyl isobutyl ketone are added and refluxed for 1 hour.
알파-p-클로로페닐-2-피리딘 클로로메탄 6 g을 메틸이소부틸 케톤 5 ml에 가해 용해 후 상기 혼합액에 90 분간에 걸쳐 적가해 준다.6 g of alpha-p-chlorophenyl-2-pyridine chloromethane is added to 5 ml of methyl isobutyl ketone and dissolved and added dropwise to the mixed solution over 90 minutes.
적가가 끝난 후 36 시간 동안 환류한다.It is refluxed for 36 hours after the addition.
실온으로 냉각 후 용매를 감압으로 제거하고 디클로로메탄 50 ml을 가하고 정제수 30 ml로 세척한다.After cooling to room temperature, the solvent was removed under reduced pressure, 50 ml of dichloromethane was added and washed with 30 ml of purified water.
무수 망초로 건조한 후 여과하고 여액을 감압에 의해 제거한다.Dry over anhydrous forget-me-not, filter and remove the filtrate by reduced pressure.
상기 표제 목적화합물 4 g (수율 80 %)을 얻는다.4 g (yield 80%) of the title compound are obtained.
1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 2.24(4H, -CH2-), 5.41 (1H), 7.06(2H, 방향핵), 7.14(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1 H NMR (CDCl 3): δ 1.63 (4H, -CH2-), 2.85 (1H), 2.24 (4H, -CH2-), 5.41 (1H), 7.06 (2H, direction nucleus), 7.14 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)
( 실시예 9) (±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘의 제조 (Example 9) (±) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of acetyl piperidine
4-하이드록시-1-아세틸피페리딘 2.4 g, 소디움 카보네이트 2.7 g, 메틸이소부틸케톤 32 ml을 가하고 1 시간 동안 환류한다.2.4 g of 4-hydroxy-1-acetylpiperidine, 2.7 g of sodium carbonate and 32 ml of methyl isobutyl ketone are added and refluxed for 1 hour.
알파-p-클로로페닐-2-피리딘 클로로메탄 6 g을 메틸이소부틸 케톤 5 ml에 가해 용해 후 상기 혼합액에 90 분간에 걸쳐 적가해 준다.6 g of alpha-p-chlorophenyl-2-pyridine chloromethane is added to 5 ml of methyl isobutyl ketone and dissolved and added dropwise to the mixed solution over 90 minutes.
적가가 끝난 후 36 시간 동안 환류한다.It is refluxed for 36 hours after the addition.
실온으로 냉각 후 용매를 감압으로 제거하고 디클로로메탄 50 ml을 가하고 정제수 30 ml로 세척한다.After cooling to room temperature, the solvent was removed under reduced pressure, 50 ml of dichloromethane was added and washed with 30 ml of purified water.
무수 망초로 건조한 후 여과하고 여액을 감압에 의해 제거한다.Dry over anhydrous forget-me-not, filter and remove the filtrate by reduced pressure.
상기 표제 목적화합물 4.6 g (수율 80 %)을 얻는다.4.6 g (yield 80%) of the title compound are obtained.
1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.3(3H), 2.85(1H), 3.24(4H, -CH2-), 5.41(1H), 7.06(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1 H NMR (CDCl 3): δ 1.63 (4H, -CH2-), 2.3 (3H), 2.85 (1H), 3.24 (4H, -CH2-), 5.41 (1H), 7.06 (2H, aromatic nucleus), 7.50 ( 1H, Directional Core), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)
( 실시예 10) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘의 제조 (Example 10) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] Preparation of -N- benzoyl piperidine
(s)-4-클로로페닐-2-피리딜 메탄올 5.6 g, 소디움 카보네이트 2.7 g, 메틸이소부틸케톤 16 ml을 가하고 30 분간 환류한 다음, 4-브로모-1-벤조일 피페리딘 3.4 g을 메틸이소부틸케톤 4 ml에 가해 용해시킨 후 상기용액에 90 분간에 걸쳐 적가해 준다.(s) 5.6 g of 4-chlorophenyl-2-pyridyl methanol, 2.7 g of sodium carbonate and 16 ml of methyl isobutyl ketone were added and refluxed for 30 minutes, followed by 3.4 g of 4-bromo-1-benzoyl piperidine. It is added to 4 ml of methyl isobutyl ketone and dissolved, and then added dropwise to the solution over 90 minutes.
완전히 가하고나서 12 시간 동안 환류한다.After complete addition, reflux for 12 hours.
실온으로 냉각 후 디클로로메탄 32 ml을 가하고 10 분간 교반 후 정제수 20 ml로 세척한다.After cooling to room temperature, 32 ml of dichloromethane is added, stirred for 10 minutes, and washed with 20 ml of purified water.
층분리를 하여 유기층을 취하고 무수 망초 0.5 g으로 건조한 다음 여과하고 여액을 감압에 의해 제거한다.The layers are separated and the organic layer is taken, dried over 0.5 g of dry forget-me-not, filtered and the filtrate is removed by reduced pressure.
상기 표제 목적화합물 7.3 g (수율 70 %)을 얻는다.7.3 g (yield 70%) of the title compound are obtained.
1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 3.34(4H, -CH2-), 5.41(1H), 7.13(2H, 방향핵), 7.18(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1H NMR (CDCl3): δ 1.63 (4H, -CH2-), 2.85 (1H), 3.34 (4H, -CH2-), 5.41 (1H), 7.13 (2H, direction nucleus), 7.18 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)
( 실시예 11) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘의 제조 (Example 11) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of benzyl piperidin-
(s)-4-클로로페닐-2-피리딜 메탄올 5.6 g, 소디움 카보네이트 2.7 g, 메틸이소부틸케톤 16 ml을 가하고 30 분간 환류한 다음, 4-브로모-1-벤질 피페리딘 3.2 g을 메틸이소부틸 4 ml에 가해 용해시킨 후 상기용액에 서서히 가해준다.(s) 5.6 g of 4-chlorophenyl-2-pyridyl methanol, 2.7 g of sodium carbonate, and 16 ml of methyl isobutyl ketone were added and refluxed for 30 minutes, followed by 3.2 g of 4-bromo-1-benzyl piperidine. It is added to 4 ml of methyl isobutyl and dissolved, and then slowly added to the solution.
완전히 가하고 나서 12 시간 동안 환류한다.After complete addition, reflux for 12 hours.
실온으로 냉각 후 디클로로메탄 32 ml을 가하고 10 분간 교반한 후 정제수 20 ml을 가한다.After cooling to room temperature, 32 ml of dichloromethane was added, stirred for 10 minutes, and 20 ml of purified water was added thereto.
실온에서 10 분간 교반 후 층분리를 하여 유기층을 취한다.After stirring for 10 minutes at room temperature, the layers are separated and the organic layer is taken.
무수 망초 0.5 g으로 건조 후 여과하여 여액을 감압에 의해 제거한다.After drying with 0.5 g of dry forget-me-not, the filtrate is removed by reduced pressure.
상기 표제 목적화합물 8.0 g (수율 80 %)을 얻는다.8.0 g (yield 80%) of the title compound are obtained.
1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 2.24(4H, -CH2-), 5.41(1H), 7.06(2H, 방향핵), 7.14(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1H NMR (CDCl3): δ 1.63 (4H, -CH2-), 2.85 (1H), 2.24 (4H, -CH2-), 5.41 (1H), 7.06 (2H, direction nucleus), 7.14 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)
( 실시예 12) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘의 제조 (Example 12) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of acetyl piperidine
(s)-4-클로로페닐-2-피리딜 메탄올 5.6 g, 소디움 카보네이트 2.7 g, 메틸이소부틸케톤 16 ml을 가하고 30 분간 환류한 다음, 4-브로모-1-아세틸 피페리딘 5.2 g을 메틸이소부틸 4 ml에 가해 용해시킨 후 상기용액에 서서히 가해준다.(s) 5.6 g of 4-chlorophenyl-2-pyridyl methanol, 2.7 g of sodium carbonate and 16 ml of methyl isobutyl ketone were added and refluxed for 30 minutes, followed by 5.2 g of 4-bromo-1-acetyl piperidine. It is added to 4 ml of methyl isobutyl and dissolved, and then slowly added to the solution.
완전히 가하고 나서 12 시간 동안 환류한다.After complete addition, reflux for 12 hours.
실온으로 냉각 후 디클로로메탄 32 ml을 가하고 10 분간 교반한 후 정제수 20 ml을 가한다.After cooling to room temperature, 32 ml of dichloromethane was added, stirred for 10 minutes, and 20 ml of purified water was added thereto.
실온에서 10 분간 교반 후 층분리를 하여 유기층을 취한다.After stirring for 10 minutes at room temperature, the layers are separated and the organic layer is taken.
무수 망초 0.5 g으로 건조 후 여과하여 여액을 감압에 의해 제거한다.After drying with 0.5 g of dry forget-me-not, the filtrate is removed by reduced pressure.
상기 표제 목적화합물 7.0 g (수율 80 %)을 얻는다.7.0 g (yield 80%) of the title compound are obtained.
1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.3(3H), 2.85(1H), 3.24(4H, -CH2-), 5.41(1H), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1 H NMR (CDCl 3): δ 1.63 (4H, -CH2-), 2.3 (3H), 2.85 (1H), 3.24 (4H, -CH2-), 5.41 (1H), 7.44 (2H, aromatic nucleus), 7.50 ( 1H, Directional Core), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)
( 실시예 13) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘의 제조 (Example 13) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of benzyl piperidin-
(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 44 g을 아세톤 184 ml에 가하고 실온에서 교반한다.44 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine are added to 184 ml of acetone and stirred at room temperature.
R-(-)-10-캄포설폰산 15.4 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.15.4 g of R-(-)-10-camphorsulfonic acid is added to 62 ml of acetone solution to dissolve and then added at 20-25 ° C.
실온에서 1 시간가량 교반한 후 생성된 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 캄포설폰산 염을 냉각하고 결정화한다.After stirring for 1 hour at room temperature, the resulting (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine camphorsulfonic acid salt is cooled and crystallized.
필요하다면 씨딩을 행한다.Seeding is done if necessary.
결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.
이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 23 g (수율 33 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 23 g (yield 33%) of the title compound is obtained.
이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 캄포설폰산 염 56.3 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.56.3 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine camphorsulfonic acid salt was added to 100 ml of dichloromethane and the reaction mixture was stirred for 10 minutes. Stir.
이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.
층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.
유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.
이렇게 하여 상기 표제 목적물을 유상으로 34 g (수율 96 %)을 얻는다.This gives 34 g (96% yield) of the title object as an oil.
1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 2.24(4H, -CH2-), 5.41(1H), 7.06(2H, 방향핵), 7.14(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1H NMR (CDCl3): δ 1.63 (4H, -CH2-), 2.85 (1H), 2.24 (4H, -CH2-), 5.41 (1H), 7.06 (2H, direction nucleus), 7.14 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)
( 실시예 14) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘의 제조 (Example 14) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] Preparation of -N- benzoyl piperidine
(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 45.5 g을 아세톤 184 ml에 가하고 실온에서 교반한다.45.5 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine are added to 184 ml of acetone and stirred at room temperature.
R-(-)-10-캄포설폰산 15.4 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.15.4 g of R-(-)-10-camphorsulfonic acid is added to 62 ml of acetone solution to dissolve and then added at 20-25 ° C.
실온에서 1 시간가량 교반한 후 생성된 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 캄포설폰산 염을 냉각하고 결정화한다.After stirring for 1 hour at room temperature, the resulting (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine camphorsulfonic acid salt is cooled and crystallized.
필요하다면 씨딩을 행한다.Seeding is done if necessary.
결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.
이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 23.6 g (수율 33 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 23.6 g (yield 33%) of the title compound are obtained.
이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 캄포설폰산 염 57.5 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.57.5 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine camphorsulfonic acid salt was added to 100 ml of dichloromethane and the reaction mixture was stirred for 10 minutes. Stir.
이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.
층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.
유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.
이렇게 하여 상기 표제 목적물을 유상으로 35 g (수율 96 %)을 얻는다.This gives 35 g (96% yield) of the title object as an oil.
( 실시예 15) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘의 제조 (Example 15) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of acetyl piperidine
(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 38.6 g을 아세톤 184 ml에 가하고 실온에서 교반한다.38.6 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetyl piperidine are added to 184 ml of acetone and stirred at room temperature.
R-(-)-10-캄포설폰산 15.4 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.15.4 g of R-(-)-10-camphorsulfonic acid is added to 62 ml of acetone solution to dissolve and then added at 20-25 ° C.
실온에서 1 시간가량 교반한 후 생성된 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 캄포설폰산 염을 냉각하고 결정화한다.After stirring for 1 hour at room temperature, the resulting (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetyl piperidine camphorsulfonic acid salt is cooled and crystallized.
필요하다면 씨딩을 행한다.Seeding is done if necessary.
결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.
이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 25.8 g (수율 40 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 25.8 g (40% yield) of the title compound are obtained.
이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 캄 포설폰산 염 25.8 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.25.8 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetyl piperidine camphorsulfonic acid salt was added to 100 ml of dichloromethane and the reaction mixture was stirred for 10 minutes. Stir.
이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.
층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.
유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.
이렇게 하여 상기 목적물을 유상으로 24 g (수율 93 %)을 얻는다.Thus, 24 g (yield 93%) of the target substance is obtained as an oil phase.
1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.3(3H), 2.85(1H), 3.34(4H, -CH2-), 5.41(1H), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1 H NMR (CDCl 3): δ 1.63 (4H, -CH2-), 2.3 (3H), 2.85 (1H), 3.34 (4H, -CH2-), 5.41 (1H), 7.44 (2H, aromatic nucleus), 7.50 ( 1H, Directional Core), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)
( 실시예 16) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘의 제조 (Example 16) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of benzyl piperidin-
(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 45.5 g을 아세톤 184 ml에 가하고 실온에서 교반한다.45.5 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine are added to 184 ml of acetone and stirred at room temperature.
(-)-디벤조일-L-타르타르산-수화물 42 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.42 g of (-)-dibenzoyl-L-tartaric acid-hydrate are added to 62 ml of acetone solution and dissolved, and then added at 20-25 ° C.
실온에서 1 시간가량 교반한 후 생성된 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 (-)-디벤조일-L-타르타르산 염을 냉각하고 결정화한다.After stirring for 1 hour at room temperature, the resulting (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine (-)-dibenzoyl-L-tartaric acid salt Cool and crystallize.
필요하다면 씨딩을 행한다.Seeding is done if necessary.
결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.
이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 30 g (수율 35 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 30 g (yield 35%) of the title compound is obtained.
이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 (-)-디벤조일-L-타르타르산 염 69.2 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.69.2 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine (-)-dibenzoyl-L-tartaric acid salt thus obtained was added to 100 ml of dichloromethane. And the reaction mixture is stirred for 10 minutes.
이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.
층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.
유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.
이렇게 하여 상기 표제 목적물을 유상으로 34.7 g (수율 98 %)을 얻는다.This affords 34.7 g (98% yield) of the title object as oil.
( 실시예 17) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘의 제조 (Example 17) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] Preparation of -N- benzoyl piperidine
(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 45.5 g을 아세톤 184 ml에 가하고 실온에서 교반한다.45.5 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine are added to 184 ml of acetone and stirred at room temperature.
(-)-디벤조일-L-타르타르산-수화물 42 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.42 g of (-)-dibenzoyl-L-tartaric acid-hydrate are added to 62 ml of acetone solution and dissolved, and then added at 20-25 ° C.
실온에서 1 시간가량 교반한 후 생성된(S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 (-)-디벤조일-L-타르타르산-염을 냉각하고 결정화한다.After stirring for 1 hour at room temperature, the resulting (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine (-)-dibenzoyl-L-tartaric acid-salt Cool and crystallize.
필요하다면 씨딩을 행한다.Seeding is done if necessary.
결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.
이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 30.6 g (수율 35 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 30.6 g (yield 35%) of the title compound are obtained.
이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 (-)-디벤조일-L-타르타르산 염 70.5 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.70.5 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine (-)-dibenzoyl-L-tartaric acid salt thus obtained was added to 100 ml of dichloromethane. And the reaction mixture is stirred for 10 minutes.
이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.
층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.
유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.
이렇게 하여 상기 표제 목적물을 유상으로 34.8 g (수율 95 %)을 얻는다.This affords 34.8 g (95% yield) of the title object as oil.
1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 3.34(4H, -CH2-), 5.41(1H), 7.13(2H, 방향핵), 7.18(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1H NMR (CDCl3): δ 1.63 (4H, -CH2-), 2.85 (1H), 3.34 (4H, -CH2-), 5.41 (1H), 7.13 (2H, direction nucleus), 7.18 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)
( 실시예 18) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘의 제조 (Example 18) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of acetyl piperidine
(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 38.6 g을 아세 톤 184 ml에 가하고 실온에서 교반한다.38.6 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetyl piperidine are added to 184 ml of acetone and stirred at room temperature.
(-)-디벤조일-L-타르타르산-수화물 42 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.42 g of (-)-dibenzoyl-L-tartaric acid-hydrate are added to 62 ml of acetone solution and dissolved, and then added at 20-25 ° C.
실온에서 1 시간가량 교반한 후 생성된 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 (-)-디벤조일-L-타르타르산-염을 냉각하고 결정화한다.(S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetyl piperidine (-)-dibenzoyl-L-tartaric acid-salt formed after stirring for 1 hour at room temperature Cool and crystallize.
필요하다면 씨딩을 행한다.Seeding is done if necessary.
결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.
이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 31 g (수율 40 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 31 g (40% yield) of the title compound is obtained.
이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 (-)-디벤조일-L-타르타르산 염 31 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.31 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetylpiperidine (-)-dibenzoyl-L-tartaric acid salt thus obtained was added to 100 ml of dichloromethane. And the reaction mixture is stirred for 10 minutes.
이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.
층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.
유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.
이렇게 하여 상기 표제 목적물을 유상으로 30 g (수율 96.7 %)을 얻는다.This gives 30 g (yield 96.7%) of the title object as an oil.
1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.3(3H), 2.85(1H), 3.34(4H, -CH2- ), 5.41(1H), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1 H NMR (CDCl 3): δ 1.63 (4H, -CH2-), 2.3 (3H), 2.85 (1H), 3.34 (4H, -CH2-), 5.41 (1H), 7.44 (2H, aromatic nucleus), 7.50 ( 1H, Directional Core), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)
( 실시예 19) (S)-4-[(4-클로로페닐)-2-피리딜 메톡시] 피페리딘의 제조 (Example 19) (S) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] piperidine Preparation of
(s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 39.3 g을 메탄올 300 ml에 가하고 팔라디움 차콜 3 g을 가한다.39.3 g of (s) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine are added to 300 ml of methanol and 3 g of palladium charcoal.
빙초산 5 ml을 같이 혼합하여 교반하면서 수소 가스를 주입시켜 상압정도를 유지하면서 12 시간 교반한다.5 ml of glacial acetic acid are mixed together, hydrogen gas is injected while stirring, and the mixture is stirred for 12 hours while maintaining the atmospheric pressure.
반응이 종료되었음을 확인한 후 여과를 하고 여액을 감압에 의해 제거해 준다.After confirming that the reaction is completed, the filtrate is removed and the filtrate is removed by reduced pressure.
상기 표제 목적화합물 36.6 g (수율 93 %)을 얻는다.36.6 g (93% yield) of the title compound is obtained.
키랄순도 : 100 %Chiral Purity: 100%
1H NMR (CDCL3) : δ 1.63(4H, -CH2-), 2.74(4H, -CH2-), 2.85(1H), 5.41(1H), 7.13(2H), 7.18(1H), 7.20(2H), 7.50(1H), 7.67(1H), 8.61(H)1 H NMR (CDCL3): δ 1.63 (4H, -CH2-), 2.74 (4H, -CH2-), 2.85 (1H), 5.41 (1H), 7.13 (2H), 7.18 (1H), 7.20 (2H), 7.50 (1 H), 7.67 (1 H), 8.61 (H)
( 실시예 20) (S)-4-[(4-클로로페닐)-2-피리딜 메톡시] 피페리딘의 제조 (Example 20) (S) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] piperidine Preparation of
(s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 40.7 g을 6 N- 염산 300 ml에 가하고 24 시간 동안 환류 교반한다.40.7 g of (s) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine are added to 300 ml of 6 N-hydrochloric acid and stirred at reflux for 24 hours.
반응이 종료된 후 진한 암모니아수로 반응액을 알카리화 한 후 클로로포름 500 ml로 3 회 추출한다.After the reaction was completed, the reaction solution was alkalined with concentrated ammonia water and extracted three times with 500 ml of chloroform.
추출액을 무수 망초로 건조하고 여과한 후 여액을 감압에 의해 제거한다.The extract is dried over anhydrous forget-me-not, filtered and the filtrate is removed by reduced pressure.
상기 표제 목적화합물 36.6 g (수율 90 %)을 얻는다.36.6 g (yield 90%) of the title compound are obtained.
키랄순도 : 100 %Chiral Purity: 100%
1H NMR (CDCL3) : δ 1.63(4H, -CH2-), 2.74(4H, -CH2-), 2.85(1H), 5.41(1H), 7.13(2H), 7.18(1H), 7.20(2H), 7.50(1H), 7.67(1H), 8.61(H)1 H NMR (CDCL3): δ 1.63 (4H, -CH2-), 2.74 (4H, -CH2-), 2.85 (1H), 5.41 (1H), 7.13 (2H), 7.18 (1H), 7.20 (2H), 7.50 (1 H), 7.67 (1 H), 8.61 (H)
( 실시예 21) (S)-4-[(4-클로로페닐)-2-피리딜 메톡시] 피페리딘의 제조 (Example 21) (S) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] piperidine Preparation of
(s)-4-[(4-클로로페닐)-(2-피리딜 메톡시]-N-아세틸 피페리딘 34.5 g을 6 N- 염산 300 ml에 가하고 48 시간 동안 환류 교반한다.34.5 g of (s) -4-[(4-chlorophenyl)-(2-pyridylmethoxy] -N-acetyl piperidine are added to 300 ml of 6 N-hydrochloric acid and stirred at reflux for 48 hours.
반응이 종료된 후 진한 암모니아수로 반응액을 알카리화 한 후 클로로포름 500 ml로 3 회 추출한다.After the reaction was completed, the reaction solution was alkalined with concentrated ammonia water and extracted three times with 500 ml of chloroform.
추출액을 무수 망초로 건조하고 여과한 후 여액을 감압에 의해 제거한다.The extract is dried over anhydrous forget-me-not, filtered and the filtrate is removed by reduced pressure.
상기 표제 목적화합물 27.3 g (수율 90 %)을 얻는다.27.3 g (yield 90%) of the title compound are obtained.
키랄순도 : 100 %Chiral Purity: 100%
1H NMR (CDCL3) : δ 1.63(4H, -CH2-), 2.74(4H, -CH2-), 2.85(1H), 5.41(1H), 7.13(2H), 7.18(1H), 7.20(2H), 7.50(1H), 7.67(1H), 8.61(H)1 H NMR (CDCL3): δ 1.63 (4H, -CH2-), 2.74 (4H, -CH2-), 2.85 (1H), 5.41 (1H), 7.13 (2H), 7.18 (1H), 7.20 (2H), 7.50 (1 H), 7.67 (1 H), 8.61 (H)
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090093724A KR101146009B1 (en) | 2009-10-01 | 2009-10-01 | Process for the preparation of active piperidine compounds by optical isolation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090093724A KR101146009B1 (en) | 2009-10-01 | 2009-10-01 | Process for the preparation of active piperidine compounds by optical isolation |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110036191A true KR20110036191A (en) | 2011-04-07 |
KR101146009B1 KR101146009B1 (en) | 2012-05-15 |
Family
ID=44044185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090093724A Active KR101146009B1 (en) | 2009-10-01 | 2009-10-01 | Process for the preparation of active piperidine compounds by optical isolation |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101146009B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130324507A1 (en) * | 2012-06-05 | 2013-12-05 | Bioprojet | Novel (aza)Benzhydryl Ether Derivatives, Their Process of Preparation and Their Use as H4-Receptor Ligands for Therapeutical Applications |
WO2019117550A1 (en) * | 2017-12-11 | 2019-06-20 | Cj Healthcare Corporation | Intermediates for optically active piperidine derivatives and preparation methods thereof |
CN113480521A (en) * | 2021-07-12 | 2021-10-08 | 成都丽凯手性技术有限公司 | Total synthesis method of bepotastine besilate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH644012A5 (en) * | 1980-01-25 | 1984-07-13 | Schaerer Ag M | OPERATING TABLE. |
TW486475B (en) | 1996-12-26 | 2002-05-11 | Ube Industries | Acid addition salt of optically active piperidine compound and process for preparing the same |
-
2009
- 2009-10-01 KR KR1020090093724A patent/KR101146009B1/en active Active
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130324507A1 (en) * | 2012-06-05 | 2013-12-05 | Bioprojet | Novel (aza)Benzhydryl Ether Derivatives, Their Process of Preparation and Their Use as H4-Receptor Ligands for Therapeutical Applications |
US9242959B2 (en) * | 2012-06-05 | 2016-01-26 | Bioprojet | (Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications |
WO2019117550A1 (en) * | 2017-12-11 | 2019-06-20 | Cj Healthcare Corporation | Intermediates for optically active piperidine derivatives and preparation methods thereof |
CN111587240A (en) * | 2017-12-11 | 2020-08-25 | 怡诺安有限公司 | Intermediate of optically active piperidine derivative and process for producing the same |
US11254641B2 (en) | 2017-12-11 | 2022-02-22 | Hk Inno.N Corporation | Intermediates for optically active piperidine derivatives and preparation methods thereof |
CN111587240B (en) * | 2017-12-11 | 2023-09-01 | 怡诺安有限公司 | Intermediate of optically active piperidine derivative and process for producing the same |
US11780810B2 (en) | 2017-12-11 | 2023-10-10 | Hk Inno.N Corporation | Intermediates for optically active piperidine derivatives and preparation methods thereof |
CN113480521A (en) * | 2021-07-12 | 2021-10-08 | 成都丽凯手性技术有限公司 | Total synthesis method of bepotastine besilate |
CN113480521B (en) * | 2021-07-12 | 2024-04-16 | 成都丽凯手性技术有限公司 | Full synthesis method of bepotastine besilate |
Also Published As
Publication number | Publication date |
---|---|
KR101146009B1 (en) | 2012-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5869657A (en) | Preparation of arthropodicidal oxadiazines | |
US7763730B2 (en) | Method preparation clopidogrel and intermediates used therein | |
KR101146009B1 (en) | Process for the preparation of active piperidine compounds by optical isolation | |
HU213473B (en) | Process for preparing flunixin | |
CH616161A5 (en) | ||
KR101041551B1 (en) | New intermediates useful for the preparation of aripiprazole and methods for preparing new intermediates and aripiprazole | |
FR2562895A1 (en) | NOVEL TRIAZOLOPYRIDIMIDINES AND PROCESS FOR THEIR MANUFACTURE | |
HU201921B (en) | New process for producing 6-acylforscholine derivatives | |
EP0819114B1 (en) | An arthropodicidal oxadiazine intermediate | |
JP2001521498A (en) | Method for producing O- (3-amino-2-hydroxy-propyl) -hydroxymic acid halide | |
KR890001241B1 (en) | Process for preparing 4-acetyl isoquinolinone | |
US4701528A (en) | Intermediates useful in the preparation of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates and process for preparing same | |
KR100699457B1 (en) | Method for preparing dibenzothione derivatives and intermediates thereof | |
KR101154767B1 (en) | New process for the preparation of optical active piperidine compounds | |
FI64136C (en) | PROCEDURE FOR FRAMSTATION OF AV D-2- (6-METHOXY-2-NAPHTHYL) -PROPIONSYRA | |
EP0639558B1 (en) | Process for preparation of 1-acyl-2-substituted-hydrazines | |
JP4973210B2 (en) | New synthesis method | |
CN119798263A (en) | A kind of ticagrelor acetyl derivative and preparation method | |
KR100201582B1 (en) | Process for preparing pyrimidyloxy benzoic acid oxime ester derivative having herbicidal activity | |
JPH10158259A (en) | Method for producing 3-alkylflavanonol derivative | |
JPH07330697A (en) | Method for producing substituted indane derivative | |
JPS6259106B2 (en) | ||
JPS61158962A (en) | Production of 1,4-dihydropyridine derivative | |
JP2003055375A (en) | Method for producing optically active hydrazine compound | |
JPS59128379A (en) | Dibenzo(b,f)(1,5)oxazocine derivative and its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20091001 |
|
PA0201 | Request for examination | ||
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20100322 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110929 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20120416 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20120507 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20120507 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20150507 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20150507 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160503 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20160503 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180508 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20180508 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190507 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20190507 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20210316 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20220509 Start annual number: 11 End annual number: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20230508 Start annual number: 12 End annual number: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20240507 Start annual number: 13 End annual number: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20250507 Start annual number: 14 End annual number: 14 |